Suzuken Co., Ltd. (TSE: 9987), one of Japan's three major pharmaceutical wholesalers, reported consolidated results for the fiscal year ended March 31, 2026 (FY3/2026) under Japanese GAAP. Net sales rose 3.6% to ¥2,486,647 million, driven by steady volume growth in prescription drug distribution across its nationwide network. Operating profit, however, declined 2.0% to ¥36,374 million as margin compression from drug price revisions offset revenue gains. Ordinary profit rose 2.4% to ¥39,744 million, aided by improved equity-method income, and net profit attributable to owners of the parent advanced 10.6% to ¥38,136 million. Basic EPS was ¥545.54 (¥454.58 a year earlier). The operating margin edged down to 1.5%, consistent with the characteristically thin-margin structure of pharmaceutical wholesale in Japan.
Revenue growth driven by prescription drug volume
Suzuken's top-line expansion reflects the ongoing structural growth in Japan's pharmaceutical market — an ageing population driving higher prescription volumes across hospital and community pharmacy channels. The company's Nagoya-headquartered distribution network serves pharmacies, hospitals, and clinics across Japan, and its scale — ranking among the top two or three pharmaceutical wholesalers by revenue — gives it leverage in negotiating with both manufacturers and dispensing pharmacies. Comprehensive income for the period surged 58.5% to ¥41,371 million, reflecting favourable moves in other comprehensive income items including valuation gains on investment securities.
Balance sheet and cash flow
Total assets rose to ¥1,155,766 million from ¥1,113,831 million a year earlier, while net assets increased to ¥416,012 million. The equity ratio edged down slightly to 36.0% from 36.6%, reflecting modest balance sheet expansion. Book value per share rose to ¥6,148.58 from ¥5,651.56. Operating cash flow recovered strongly to ¥33,566 million, a sharp reversal from the -¥65,079 million recorded in FY25, which had been distorted by working-capital movements. Investing cash flow generated ¥12,817 million, and financing outflows were ¥33,336 million. Cash and equivalents at year-end stood at ¥131,604 million.
Dividend maintained at ¥100; stock split and FY27 guidance
Suzuken declared a full-year dividend of ¥100 per share (¥50 interim + ¥50 year-end) for FY3/2026, unchanged from the prior year, for a payout ratio of 18.3%. The company announced a 1-for-2 stock split effective October 1, 2026, after which the share count will double. For FY3/2027, Suzuken guides net sales of ¥2,563,000 million (+3.1%), operating profit of ¥31,200 million (-14.2%), ordinary profit of ¥34,300 million (-13.7%) and net profit of ¥25,000 million (-34.4%). On a post-split basis, EPS is guided at ¥184.81 (equivalent to ¥369.62 pre-split). The FY27 profit decline reflects headwinds from Japan's April 2026 NHI drug-price revision cycle, which periodically compresses wholesale margins industry-wide. The year-end dividend for FY27 is guided at ¥30 per share on a post-split basis (equivalent to ¥60 pre-split), bringing the expected full-year total to ¥90 post-split (or ¥120 pre-split).
| Metric | FY3/2026 | FY3/2025 | YoY |
|---|---|---|---|
| Net sales (¥ billion) | 2,486.6 | 2,400.0 | +3.6% |
| Operating profit (¥ billion) | 36.4 | 37.1 | -2.0% |
| Ordinary profit (¥ billion) | 39.7 | 38.8 | +2.4% |
| Net profit attrib. to owners (¥ billion) | 38.1 | 34.5 | +10.6% |
| EPS (¥) | 545.54 | 454.58 | +20.0% |
| Operating margin | 1.5% | 1.5% | — |
| Equity ratio | 36.0% | 36.6% | -0.6pp |
| Total assets (¥ billion) | 1,155.8 | 1,113.8 | +3.8% |
| Operating cash flow (¥ billion) | 33.6 | -65.1 | N/M |
| Annual dividend (¥, pre-split) | 100.00 | 100.00 | — |
| FY27 operating profit guidance (¥ billion) | 31.2 | — | -14.2% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.